Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTemIS-Eso: Monalizumab with Chemoradiotherapy in Esophageal Cancer
NCT03307941Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab in esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), gastroesophageal junction adenocarcinoma, sponsored by Institut Jules Bordet. Planned start Jul 2017; status: withdrawn.
02
Drugs
monalizumab
03
Conditions
esophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03307941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307941.